Joseph Leach is moving into the CMO slot at Prime.
Prime Therapeutics LLC has named Joseph Leach, MD, as senior vice president and chief medical officer.
Leach brings over 20 years of experience to the Minnesota PBM as a clinician, researcher and health care leader to his role. He will lead the expansion of Prime’s specialty management capabilities and help shape the company’s total drug management strategy, according to a company press release.
“I couldn’t be more pleased to welcome Dr. Leach to Prime,” Prime’s President CEO, Ken Paulus, was quoted as saying in the press release. “Dr. Leach’s depth of experience in oncology therapy coupled with his devotion to patient-focused care will offer superb value to our clients and their members.”
Prime, which is headquartered in Eagan, Minnesota, a suburb of the Twin Cities, is owned by 18 Blue Cross and Blue Shield plans. In December, Prime and Express Scripts announced the formation of a collaboration. Express is now owned by Cigna.
Leach has held numerous leadership roles including medical director of Virginia Piper Cancer Institute in Minneapolis, past president of the Minnesota Society of Clinical Oncology and principal investigator for the Metro-Minnesota Community Oncology Research Consortium. He has also held national leadership positions in research including committee chair for the Eastern Cooperative Oncology Group and membership in the National Cancer Institute’s Thoracic Malignancy Steering Committee, says the press release from Prime,.
Leach graduated from St. Olaf College with a BA in biology and earned his MD at the University of Minnesota. He completed training in internal medicine and medical oncology at the University of Oklahoma in Oklahoma City and is a board-certified medical oncologist.
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More